OSBORNE DAVID W 4
4 · Arcutis Biotherapeutics, Inc. · Filed Mar 3, 2021
Insider Transaction Report
Form 4
OSBORNE DAVID W
Chief Technical Officer
Transactions
- Sale
Common Stock
2021-03-01$34.57/sh−780$26,968→ 237,253 total
Footnotes (2)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021.
- [F2]Includes 6,750 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.